- Home
- KRYS vs DNLI Comparison
KRYS vs DNLI Comparison
Compare KRYS & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRYS
- DNLI
- Stock Information
- Founded
- KRYS 2015
- DNLI 2013
- Country
- KRYS United States
- DNLI United States
- Employees
- KRYS N/A
- DNLI N/A
- Industry
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KRYS Health Care
- DNLI Health Care
- Exchange
- KRYS Nasdaq
- DNLI Nasdaq
- Market Cap
- KRYS 5.1B
- DNLI 4.5B
- IPO Year
- KRYS 2017
- DNLI 2017
- Fundamental
- Price
- KRYS $172.50
- DNLI $27.39
- Analyst Decision
- KRYS Strong Buy
- DNLI Strong Buy
- Analyst Count
- KRYS 8
- DNLI 11
- Target Price
- KRYS $199.43
- DNLI $38.90
- AVG Volume (30 Days)
- KRYS 236.9K
- DNLI 718.4K
- Earning Date
- KRYS 11-04-2024
- DNLI 11-06-2024
- Dividend Yield
- KRYS N/A
- DNLI N/A
- EPS Growth
- KRYS N/A
- DNLI N/A
- EPS
- KRYS 1.77
- DNLI N/A
- Revenue
- KRYS $241,519,000.00
- DNLI N/A
- Revenue This Year
- KRYS $485.65
- DNLI N/A
- Revenue Next Year
- KRYS $58.64
- DNLI $283.75
- P/E Ratio
- KRYS $100.04
- DNLI N/A
- Revenue Growth
- KRYS 2722.80
- DNLI 204.74
- 52 Week Low
- KRYS $96.73
- DNLI $14.56
- 52 Week High
- KRYS $219.34
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- KRYS 42.62
- DNLI 45.97
- Support Level
- KRYS $182.26
- DNLI $26.17
- Resistance Level
- KRYS $207.84
- DNLI $33.33
- Average True Range (ATR)
- KRYS 8.55
- DNLI 1.47
- MACD
- KRYS -0.10
- DNLI 0.02
- Stochastic Oscillator
- KRYS 20.00
- DNLI 23.65
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.